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Abstract
Background: Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring
before adulthood. A pilot clinical trial to determine the feasibility of an RCT was conducted and is reported here.
Methods: 12 participants 12 to 35 years old were recruited to a prospective open-label pilot trial and treated with
60 mg of standardized G. biloba two times per day for 12 weeks. The criteria for feasibility included successful
recruitment, 75% or greater retention, effectiveness and lack of serious adverse reactions. Effectiveness was
assessed using the Vitiligo Area Scoring Index (VASI) and the Vitiligo European Task Force (VETF), which are
validated outcome measures evaluating the area and intensity of depigmentation of vitiligo lesions. Other
outcomes included photographs and adverse reactions. Safety was assessed by serum coagulation factors
(platelets, PTT, INR) at baseline and week 12.
Results: After 2 months of recruitment, the eligible upper age limit was raised from 18 to 35 years of age in order
to facilitate recruitment of the required sample size. Eleven participants completed the trial with 85% or greater
adherence to the protocol. The total VASI score improved by 0.5 (P = 0.021) from 5.0 to 4.5, range of scale 0 (no
depigmentation) to 100 (completely depigmented). The progression of vitiligo stopped in all participants; the total
VASI indicated an average repigmentation of vitiligo lesions of 15%. VETF total vitiligo lesion area decreased 0.4%
(P = 0.102) from 5.9 to 5.6 from baseline to week 12. VETF staging score improved by 0.7 (P = 0.101) from 6.6 to
5.8, and the VETF spreading score improved by 3.9 (P < 0.001)) from 2.7 to -1.2. There were no statistically
significant changes in platelet count, PTT, or INR.
Conclusions: The criteria for feasibility were met after increasing the maximum age limit of the successful
recruitment criterion; participant retention, safety and effectiveness criteria were also met. Ingestion of 60 mg of
Ginkgo biloba BID was associated with a significant improvement in total VASI vitiligo measures and VETF spread,
and a trend towards improvement on VETF measures of vitiligo lesion area and staging. Larger, randomized
double-blind clinical studies are warranted and appear feasible.
Trial Registration: Clinical trials.gov registration number NCT00907062
Background
Vitiligo is a depigmentation disorder affecting 1-4% of the
world population [1-3]. Fifty percent of cases appear
before the age of 20 [4-7], with the disfigurement resulting
in psychiatric morbidity in 16 to 35% of those affected [8].
Depression, sleep disturbances, suicidal thoughts, suicidal
attempts, difficulties in relationships and avoidance of
social situations have been reported in individuals afflicted
by vitiligo before adulthood [8,9]. Vitiligo can be confused
with leprosy, leading to further stigmatization [10]. The
Greater Toronto Area (GTA) has significant Caribbean,
African, and South Asian populations, which are doubly at
risk. The darker skin makes the vitiligo more apparent,
and the presence of lesions similar to endemic communic-
able diseases carry difficult cultural stigma.
The disease pathogenesis of vitiligo has not been fully
elucidated. Autoimmune, biochemical and oxidative stress,
genetic, neuronal and environmental factors are thought
to interact and contribute to the development of vitiligo
[11]. Forschner points to four distinct theories [12]. The
first is an “autoimmune hypothesis” supported by the
observation that several autoimmune diseases often appear
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display elevated levels of serum antibodies to melanocytic
antigens (tyrosinase and tyrosinase-related proteins 1
and 2) [11,12]. Second is the “neuronal hypothesis” which
states that altered reactions of melanocytes to neuropep-
tides and catecholamines are responsible for melanocyte
destruction [12]. Several studies have found that dopamine
can induce apoptosis in human melanocytes [13,14]. The
neuronal hypothesis is further supported by the findings
that there is close contact between melanocytes and nerve
endings in depigmented skin, an observation rarely seen in
normal skin [12]. Degenerated and regenerated autono-
mous nerve fibers and thickened basement membranes of
Schwann cells can also be found within vitiligo lesions
[12]. Third is the “self-destruct hypothesis”, where melano-
cytes self-destruct due to defects in protective mechanisms
responsible for removing toxic melanin precursors [12].
This is thought to lead to the accumulation of melanotoxic
indole derivatives and free radicals [12]. Fourth is the “bio-
chemical hypothesis” which postulates an overproduction
of a tyrosine hydroxylase cofactor, hydrobiopterin, result-
ing in increased catecholamine synthesis [12]. This is
thought to result in increased reactive oxygen species that
are toxic to melanocytes [12]. This is supported by find-
ings of reduced catalase and higher concentrations of
hydrogen peroxide in affected and unaffected skin of viti-
ligo sufferers [12,15].
Conventional treatments for vitiligo include photoche-
motherapy (PUVA), phototherapy (UVB), vitamin D3
analogues, topical corticosteroids, topical immunomodu-
lators, excimer laser, and surgery. These treatment
options have limited success [1,11,12], and some present
significant risks, including suspected increases in skin
cancer risk by PUVA, skin atrophy with corticosteroids,
and skin boils with UVB therapy [1,11,12]. The low ben-
efit to risk ratios of these therapies and the high psycho-
logical impact of vitiligo make the search for a safe and
effective alternative approach critical.
A systematic review of natural health product (NHP)
treatments for vitiligo [16] identified several approaches
showing positive results, including topical tocopherol
[17], topical vitamin D3 [18,19], and oral l-phenylalanine
[20,21], and Ginkgo biloba [3]. However, the trials were
generally of poor quality and the products were often
tested as adjuncts to UVA or UVB. One trial using only
Ginkgo biloba monotherapy in adults showed promising
results but was of poor methodological quality.
The specific mechanism of the action of Ginkgo biloba
in vitiligo is unknown. Parsad points out that ginkgo is
known to have anti-inflammatory, immunomodulatory,
and antioxidant properties [3], thus potentially impact-
ing the oxidative stress mechanisms of vitiligo. Ginkgo
and its constituents have been shown to attenuate
oxidative stress in macrophages and endothelial cells
[22], scavenge superoxides [23], and protect against
UVB-induced toxicity [24].
As stress or anxiety have been postulated to be
involved to the mechanisms of vitiligo pathogenesis,
ginkgo’s anxiolytic effect may also contribute to its use in
the treatment of vitiligo. Several studies using animal
models report that ginkgo can significantly decrease the
detrimental effects of learned helplessness [25], increase
intake of novel food in emotional hypophagia, and
increase time spent in the open on the elevated plus
maze. These effects are similar to those demonstrated for
anxiolytic drugs such as diazepam and buspirone [25]. In
auditory perturbation stress the detrimental effects of
stress indicated by increased errors and increases in
plasma concentrations of epinephrine, norepinephrine,
and corticosterone were decreased by Ginkgo biloba
extract EGb 761 [25]. Marcilhac also showed that long
term administration of ginkgo extract EGb 761 resulted
in decreased basal corticosterone secretion, corticotro-
phin releasing hormone (CRH) and arginine vasopressin
(AVP) gene expression [26]. Under intense surgical
stress, CRH, ACTH, and corticosterone plasma concen-
trations were elevated in control animals, but signifi-
cantly less so in ginkgo treated animals [26]. Woelk
postulates that these findings suggest that EGb 761
modulates the activity of the hypothalamic-pituitary-
adrenocortical (HPA) axis [25].
T h ea n x i o l y t i ce f f e c to fGinkgo biloba has also been
demonstrated in humans. Ginkgo biloba has been
reported to improve symptoms associated with dementia
including anxiety [27]. Jezova showed that ginkgo extract
EGb 761 significantly attenuated a stress-induced rise in
systolic and diastolic blood pressure, and maintained nor-
mal salivary cortisol, while the salivary cortisol increased
in the placebo group [28]. Hemmeter et al demonstrated
improved sleep efficiency and reduced awakenings with
ginkgo intake. In a 107 patient randomized, double blind,
placebo controlled 4 week trial Woelk et al demonstrated
a dose dependent decrease on the Hamilton rating scale
for anxiety (HAMA), indicating an improvement in anxi-
ety [25]. While the mechanism of action of Gingko biloba
in the treatment of vitiligo is unknown, ginkgo’s immu-
nomodulatory, antioxidant, and anxiolytic properties may
be of benefit to vitiligo sufferers. The ease of taking an
oral pill, the relatively low cost, and the low frequency of
adverse reactions with G. biloba [29] make its use for
vitiligo tempting, but the poor quality of the study and
lack of replication of the findings make clinical conclu-
sions difficult. Here we report on a pilot study using
G. biloba for the treatment of vitiligo in Canadian adoles-
cents and young adults in the GTA using a validated
outcome.
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Study Design
This prospective, open-label, non-randomized, feasibility
trial was conducted in a western suburb of the Greater
Toronto Area (GTA) from May to November 2009. The
primary objective was to determine feasibility and sam-
p l es i z ee s t i m a t e sf o ral a r g er randomized controlled
trial of ginkgo for vitiligo. The pre-determined criteria
used to judge feasibility were:
￿ successful recruitment of 12 participants in
3 months
￿ 75% participants completing the trial
￿ at least 25% of participants achieving a clinically
significant 30% repigmentation
￿ lack of serious adverse reactions requiring hospita-
lization or threatening the life of participants, as
defined by the World Health Organization [30]
Participants and Setting
We planned to include a convenience sample of male or
female participants, aged 12 to 18 years old, with vitiligo
vulgaris of any duration as diagnosed by a doctor, and a
minimum VASI depigmentation score corresponding to
a3c m
2 completely (100%) depigmented lesion, or a
6c m
2 50% depigmented lesion.
Participants were recruited from the GTA. Study
advertisements were made via magazines, posters, on-
line, and cultural centers, and via letters to dermatolo-
gists and pediatricians in the western GTA. The study
was approved by the Health Sciences Research Ethics
Board at the University of Toronto (REB), and the Nat-
ural Health Products Directorate at Health Canada
(NHPD). Informed consent was obtained from all
enrolled participants (or their guardians). For all adoles-
cent participants, assent of the participants was sought
in addition to parental consent. The conduct of the trial
complied with the Helsinki Declaration for studies in
humans.
T h es t u d yt o o kp l a c ea tap r i v a t ep r a c t i c ei nc e n t r a l
Mississauga, a western suburb of the GTA. The study
was funded by the Interdisciplinary Network for Com-
plementary & Alternative Medicine Research (IN-CAM).
The study product was provided free of charge by Ser-
oyal International Inc. who had no input in the design
and conduct of the study nor the interpretation and
publishing of the results.
Study Interventions
The study comprised of 4 visits: initial, and 3 follow up
visits every 4 weeks. Total length of treatment was 12
weeks for each participant.
During the initial visit the presence of vitiligo was ver-
ified under Wood’s lamp. Inclusion and exclusion cri-
t e r i aw e r ea s s e s s e d ,w h i c he x c l u d e da n y o n ew h oh a d
treatment for vitiligo or used of Ginkgo biloba within
2 months of study onset or during treatment. Partici-
pants’ background information, information for the Viti-
ligo European Task Force (VETF) form [31], Vitiligo
Area Scoring Index (VASI) [32], and pictures under
incandescent and Wood’s lamp were also collected dur-
ing the initial visit.
A blood sample (6-8 ml) was obtained to determine
coagulation status of participants, including complete
blood count (CBC), partial thromboplastin time (PTT),
and prothrombin time (INR).
At the end of the initial visit, participants were given a
30 day supply of the supplement (Ginkgo plus by Seroyal,
Health Canada Natural Product Number 80010368) con-
taining 60 mg of Ginkgo biloba (standardized to 15 mg
ginkgoflavonglycosides and 4 mg terpene lactones per
pill) and instructed to take 1 oral capsule twice per day
10 minutes before breakfast and dinner for the duration
of the trial. No other treatments for vitiligo were per-
mitted, but all other medications and medical treatments
were allowed and monitored via diaries. Participants
were then scheduled for a follow up visit in 4, 8, and
12 weeks.
Sequential follow ups took place every 4 weeks, and
included a diary and oral review of other medication
use, adverse reactions, and compliance via collection
and counting of Ginkgo biloba capsules returned. Pro-
gression of vitiligo was monitored via the Vitiligo Area
Scoring Index (VASI), via the measurement criteria
established by the VETF, and via photographs of vitiligi-
nous lesions under incandescent and Wood’sl i g h t .A t
the end of each follow up, participants were given a new
30 day supply of G. biloba. Orest Szczurko (OS) per-
formed the VASI and VETF assessments after training
by Neil Shear (NS). OS was not blinded to treatment
allocation. At the end of study at week 12, blood sam-
pling was repeated.
Withdrawal of subjects
Participants were free to withdraw at any time during
the study. Upon indication of withdrawal, participants
were asked about the reason for withdrawal, and about
any adverse reactions. After withdrawing, participants
were not contacted again unless they indicated their
wish to receive results of the study by mail.
Outcome Measures
The primary outcome measure was the VASI evaluated
at baseline and week 12. The VASI is a validated vitiligo
outcome measure [32] that is used to determine the
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depigmentation) to 100 (complete depigmentation of the
entire body). The VASI takes into account the size and
the degree of depigmentation of vitiligo lesions. The
VASI score is calculated by multiplying the sum of the
area of each lesion by the percent depigmentation of the
lesion. The area of each lesion is measured in percent of
total body surface using the rule of nines, where the
palm plus volar surface of all the digits = 1%. The inten-
sity of depigmentation of each lesion is approximated on
a 0-100 percent scale.
Secondary outcome measures of vitiligo included
the VETF score, digital photographs under incandes-
cent and Wood’s light scored at baseline and final week
12 follow up visit. The VETF is designed to evaluate the
area of vitiligo lesions, staging, and disease activity. The
VETF scoring form includes background information on
disease duration, disease activity, family vitiligo history,
and degree to which vitiligo impacts the participant’s
life. It also assesses Fitzpatrick’s skin type, presence of
thyroid or other autoimmune diseases, and the presence
and number of halo nevus. The area of each lesion is
measured in percent of total body surface (where the
palm plus volar surface of all the digits = 1%). The viti-
ligo staging score is assessed from 0 to 3 (0 = normal
pigmentation, 1 = incomplete depigmentation, 2 = com-
plete depigmentation, 3 = complete depigmentation plus
significant hair whitening) and summed for 5 body
regions. Thus the staging score range is from 0 to 15.
Disease activity is assessed from -1 indicating regressive
vitiligo to + 1 indicating progressive vitiligo for each of
5 body regions, thus giving a range from -5 to +5. The
VETF and VASI were scored by one of the investigators
(OS) after training by a practicing dermatologist, profes-
sor and chief of dermatology at the University of
Toronto (NS).
All depigmented lesions were photographed with a
Panasonic Lumix 9.1 MP digital camera next to a mm/cm
ruler.
Adverse events were recorded by participants in a
diary, or orally communicated to one of the investiga-
tors (OS). At each follow up, the diary was collected
and participants were asked: “Since our last visit, did
you experience any odd or unusual symptoms?” In the
event of an adverse event, patients were instructed to
note and record the intensity, timing, and description
of any adverse events. The World Health Organiza-
tions definition of adverse events was used [30], and
correlation with treatment was rated by the clinicians
(OS and NS).
Sample Size Calculation and Statistical Analysis
The primary outcome measure was the difference in
VASI scores between baseline and week 12. With an
alpha set at 0.05 and beta of 0.20, and assuming a base-
line VASI score of 20, a standard deviation of 7 [33],
and a 30% improvement, we estimated 10 subjects were
required. Allowing for 2 dropouts, 12 participants were
deemed sufficient to demonstrate a large treatment
effect if present, and demonstrate feasibility of recruit-
ment, retention, safety, and assessment of outcome mea-
sures to allow for a calculation of effect size for a larger
randomized clinical trial planned for the future. Scores
were compared using a paired t-test, where a p-value of
< 0.05 was considered significant.
Results
Recruitment and follow up
Initial recruitment of participants 12 to 18 years of age
proved difficult. After two months of recruitment, the
upper age limit was increased to 35 years. Eight partici-
pants under 18 and four participants aged 18-35 were
recruited (eight female and four male). Eleven partici-
pants completed the 12 week study with a mean compli-
ance rate of 87% (range 71%-97%), attended all follow
up visits, and were included in the statistical analysis.
One female participant dropped out after the first
4 week follow-up, stating a loss of interest in the study.
Participant characteristics are in Table 1.
Efficacy
The status of vitiligo over the study period is displayed
in Table 2. The total VASI score showed a significant
improvement of 0.5 (P = 0.021) from baseline (4.97) to
week 12 (4.47) (Table 2). The trunk, with a VASI score
improvement of 0.2 (P = 0.105) and legs, with an
improvement of 0.196 (P = .228) showed the greatest
responses.
The mean percent improvement in the VASI score
was 15%, with 2 participants improving greater than
30% and one achieving a 27% improvement in total
VASI score. Three others showed improvements in
VASI from 11 to 18%. Of the eleven participants who
completed the trial, two experienced no change and one
experienced a very small 0.4% improvement. Figure 1
charts the baseline and week 12 VASI scores.
The VETF scores for area, staging, and disease activity
a r es h o w ni nT a b l e3 .T h eV E T Fs c o r e so ft o t a la r e ao f
vitiligo lesions decreased from 5.91 to 5.56, a decrease
of 0.36 (P = 0.102) on the VETF, translating to a 6%
decrease in lesion size. The VETF staging score also did
not show significant improvement, but did show a trend
toward improvement in all body areas, with total staging
change improving from 6.5 to 5.8, a change of 0.73 (P =
0.101), or 11%. The treatment had a significant impact
on arresting the spread of vitiligo, improving the total
spreading score from 2.7 to -1.1, a 3.9 point difference
(P =< 0.001).
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participants who improved the greatest, and those who
did not improve at all. Of the three participants that
improved the greatest: two had progressive vitiligo,
while one had non progressive; two were male, one was
female; two had Fitzpatricks skin type 5 and one Fitzpa-
trick skin type 4. They were 13, 14 and 19 years old,
and had suffered with vitiligo for 10, 14 and 2 years and
had started study treatment on July 20, July 27, and
June 11 2009 respectively. One had vitiligo on hands,
the others did not. Two had vitiligo on the torso and all
three had vitiligo on the lower body but only one on
feet.
In contrast, of the three participants who did not
improve significantly: two were female; they were aged
12, 16 and 22 with disease duration of 4, 6 and 9 years
and started study treatment on June 9, June 9, and July
16, 2009 respectively. Two had non progressive vitiligo,
and one progressive. Two had Fitzpatricks skin type 5
and one type 4. All three had vitiligo on hands; two had
vitiligo on upper extremities. All three had vitiligo on the
torso area as well as the lower extremities and the feet.
Safety
Serum coagulation parameters measured at baseline and
week 12 (Table 4) demonstrated no significant changes.
One case of watery diarrhea of mild intensity that
developed 43 days after starting the Ginkgo biloba was
reported by a 13 year old male participant. The partici-
pant continued to take the Ginkgo biloba and the diar-
rhea resolved within 24 hours without any treatment or
protocol deviations. The participant reported having a
similar one day bout of watery diarrhea two months
before entering the study, when not taking any supple-
ments. The participant, his parents, and the study coor-
dinator agreed that the watery diarrhea episode was
likely unrelated to the Ginkgo biloba supplement. There
were no other adverse events reported by participants.
Discussion
In this pilot trial, we did not demonstrate feasibility
according to the four criteria of recruitment set-out a-
priori: 12 participants in 3 months, 75% retention, 25%
of participants achieving 30% repigmentation based on
the VASI, and lack of serious adverse reactions. The pri-
mary challenge for achieving feasibility was the recruit-
ment of 12 participants aged 12 to 18 years old in the
specified time period. The initial recruitment was lim-
ited to pediatric patients since 50% of vitiligo cases
appear before 20 years old, and vitiligo is known to have
significant psychological impact. It could be argued that
the adolescent years are some of the most psychologi-
cally fragile, where looks and social pressures have the
most impact, thus the adolescent population was tar-
geted for this study as the need to treat their vitiligo
was perceived to be the greatest. Although many people
inquired about the study, we had difficulty recruiting
the young participants specified in the inclusion criteria.
After two months of recruitment, the upper age limit
was raised to 35 years old, and this resulted in achieve-
ment of the required sample size. Eleven of 12 partici-
pants, or 92%, completed the trial.
Table 1 Baseline Vitiligo European Task Force
characteristics of participants starting treatment
Sex
Female 8
Male 4
Mean Years of Age (range) 18 (12-29)
Fitzpatrick’s phototypes
I1
II 0
III 0
IV 2
V9
VI 0
Duration of disease, mean years (range) 5.96 (2-17)
Ethnicity
Caucasian 2
South Asian 9
South American 1
Disease activity
Progressive 7
Non progressive 5
Previous repigmentation
after treatment 11
spontaneous 0
no repigmentation 1
Depigmentation on scars 5
Stress at onset 2
Stress as precipitating factor 2
Itch before lesions 3
Vitiligo on genitals 3
Thyroid disease
Yes 1
No 11
Thyroid antibodies
Yes 0
No 9
unknown 3
Family history of premature gray hair 4
Family history of vitiligo 3
Degree to which vitiligo affects everyday life (out of 10, 10
being the worst) (SD)
3.7 (1.84)
History of autoimmune disease 0
Family history of thyroid or other autoimmune disease 1
Halo Nevus 0
n = 12, SD = standard deviation.
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vide preliminary evidence that ginkgo may have a role in
the management of vitiligo. Two participants achieved
greater than 30% improvement in VASI, with another
achieving 27%, and three more 11 to 18% improvement.
The percentage of improvement of VETF scores of the
three most improved participants were 6,7, and 29% on
area; 0,40, and 50% on staging; and 100, 150, and 133%
on spread (the spreading measure ranges from -5 when
the vitiligo is spreading to +5 when it is repigmenting
thus allowing greater than 100% improvement).
Our findings are consistent with a previous report
showing effectiveness in treating vitiligo with Ginkgo
biloba [3]. In a double blind randomized trial conducted
in India, Parsad et al reported that 40 mg of Ginkgo
biloba three times per day for 6 months arrested the
spread of vitiligo in 20 out of 25 participants in the
active group, and induced marked (75% or greater)
repigmentation in 10 of those participants.
Several factors could account for the difference in the
m a g n i t u d eo fe f f e c tb e t w e e nt h ep r e s e n ts t u d ya n dt h e
study by Parsad [3]. First, the duration of treatment in
our study was 12 weeks, compared with 6 months. Sec-
ondly, we were unable to utilize exactly the same Ginkgo
biloba extract used by Parsad, though both extracts were
standardized to the same type and amount of ginkgofla-
vonglycosides. Third, we utilized 60 mg of Ginkgo biloba
twice per day, while the Parsad used 40 mg three times
per day. While the daily dosage of the standardized
ginkgoflavonglycosides and Ginkgo biloba is the same,
there could be a benefit to taking the G. biloba in more
frequent doses. It is also possible that genetic differences
between the populations of the two studies had an
impact, although this is unlikely as 9 of the 12 recruited
participants in this study were of South Asian origin. As
our study was performed in Toronto and the other in
India, dietary and social differences between the two
populations might have affected the results. The most
likely confounding factor, however, is sun exposure, as it
can stimulate the proliferation of melanocytes and affect
Table 2 Vitiligo Area Scoring Index scores at baseline and week 12, n = 11
Area % area of vitiligo (SD) extent of depigmentation
(0,10,25,50,75,90,100) (SD)
VASI score (SD)
hands (0-4%) baseline 1.08 (0.93) 37.27 (35.73) 0.51 (0.56)
week 12 1.08 (0.93) 35.91 (34.27) 0.50 (0.57)
change 0.00 p = 0 -1.36 p = 0.21 -0.01 p = 0.21
upper extremities (0-18%) baseline 1.10 (1.69) 34.55 (41.02) 0.70 (1.38)
week 12 1.10 (1.69) 30.91 (35.48) 0.63 (1.18)
change 0.00 p = 0 -3.64 p = 0.20 -0.07 p = 0.35
trunk (0-36%) baseline 2.87 (4.04) 69.64 (32.58) 1.66 (1.53)
week 12 2.85 (4.04) 58.64 (32.95) 1.43 (1.57)
change -0.02 p = 0.36 -11.00 p = 0.11 -0.22 p = 0.10
lower extremities (0-36%) baseline 2.12 (2.12) 57.73 (29.78) 1.32 (1.57)
week 12 2.12 (2.13) 50.00 (26.36) 1.13 (1.37)
change 0.00 p = 0.36 -7.73 p = 0.08 -0.20 p = 0.23
feet (0-6%) baseline 1.14 (1.41) 50.00 (41.17) 0.79 (1.26)
week 12 1.12 (1.40) 50.00 (41.17) 0.78 (1.26)
change -0.02 p = 0.36 0.00 p = 0 0.00 p = 0.36
total VASI (0-100%) baseline 4.97 (4.74)
week 12 4.47 (4.69)
change -0.51 p = 0.02
SD, standard deviation.
Figure 1 Baseline and week 12 VASI scores. Graph of individual
participants’ Vitiligo Area Scoring Index scores at baseline and end
of study (week 12).
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vitiligo [1,34]. An attempt was made to compensate for
this by starting the study in May, but some participants
were recruited late in the summer, and completed the
12 week study in November, thus experiencing substan-
tial decreasing intensity of sun exposure over the last
few months of their treatment.
Most studies of vitiligo treatment with phototherapy
set a 75% repigmentation rate as cosmetically accepta-
ble, and are able to achieve it in 12.5 to 75% of patients
after one year of treatment [35]. By comparison, other
studies utilizing the VASI as the primary outcome mea-
sure have found a 43% improvement with narrow band
UVB therapy [32]. Thus a 15% improvement in VASI
after 3 months of treatment is much smaller than can
be achieved with other therapies over a longer duration.
There were no adverse events attributed to the study
herb, and Ginkgo biloba did not adversely affect serum
platelet, PTT, or INR coagulation parameters. Given the
inclusion of adolescent participants in this study, much
care was taken to monitor adverse events experienced
due to the taking of Ginkgo biloba. The most concerning
was the potential of Ginkgo biloba to reduce coagulation
[36-40]. To ensure participant safety and to inform the
impact of Ginkgo biloba on coagulation parameters, the
baseline and week 12 serum platelet count, PTT, and
INR levels were measured. There was an unexpected
high proportion of participants with elevated PTT levels
at baseline (3 of 11). The PTT showed a decreasing trend
toward normalization by the end of the study. It is also
interesting that the mean platelet count increased by
week 12, moving opposite of the expected anticoagulant
effect of ginkgo, while the INR remained the same. Our
results suggest that Ginkgo biloba did not have a negative
impact on these blood clotting parameters. The impact
of Ginkgo biloba on serum coagulation was not the pri-
mary outcome of our study, thus the study was not pow-
ered to evaluate the significance of these results.
As one of the top selling herbal medicines in the United
States [41], and accounting for 1% of total prescriptions in
Germany [39], the use of Ginkgo biloba for vitiligo is
appealing due to the ease of use of taking an oral readily
available over the counter product compared with fre-
quent and lengthy ultraviolet phototherapy sessions, and
the relatively inexpensive cost of the herbal supplement
when compared to phototherapy [42]. Further, the rela-
tively good safety profile of gingko [29] make it appealing
for self administration by vitiligo sufferers. However, it is
recommended that any attempt to use ginkgo in the man-
agement of vitiligo should be carefully monitored by a
Table 3 The Vitiligo European Task Force scores at baseline and week 12, n = 11
area % area (SD) staging (0-3) (SD) spreading (-1 to 1) (SD)
head and neck (0-9%) baseline 0.79 (0.94) 1.55 (0.93) 0.73 (0.47)
week 12 0.73 (0.83) 1.27 (0.90) -0.36 (0.50)
change -0.06 p = 0.27 -0.27 p = 0.21 -1.09 p = 0.00
trunk (0-36%) baseline 1.33 (1.31) 1.55 (1.04) 0.82 (0.40)
week 12 1.30 (1.30) 1.45 (1.04) -0.45 (0.52)
change -0.03 p = 0.21 -0.09 p = 0.36 -1.27 p = 0.00
arms (0-18%) baseline 1.81 (2.17) 1.36 (0.81) 0.55 (0.52)
week 12 1.77 (2.06) 1.27 (0.79) -0.09 (0.54)
change -0.05 p = 0.36 -0.09 p = 0.36 -0.64 p = 0.00
legs (0-36%) baseline 1.99 (2.25) 2.09 (0.54) 0.64 (0.50)
week 12 1.76 (1.76) 1.82 (0.75) -0.27 (0.79)
change -0.23 p = 0.26 -0.27 p = 0.09 -0.91 p = 0.02
totals (0-100%) baseline 5.91 (4.53) 6.55 (1.92) 2.73 (1.35)
week 12 5.56 (4.27) 5.82 (1.94) -1.18 (1.25)
change -0.36 p = 0.10 -0.73 p = 0.10 -3.91 p = 0.00
SD, standard deviation.
Table 4 Blood coagulation parameters at baseline and week 12, n = 11
Platelet count * range APTT ** range INR *** range
baseline 262 184-412 36.5 28-53 1.15 1.0-1.5
week 12 284 173-441 34.6 26-40 1.15 1.0-1.3
*Platelet count test range 145 – 400.
**APTT test range 26 – 37s.
***INR test range 0.9 – 1.3.
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questions about the correct dose, its true effectiveness,
interactions with other conditions or therapies, and possi-
ble adverse reactions.
Limitations
There are several limitations to our pilot study that war-
rant discussion. The purpose of this study was to assess
the feasibility of studying ginkgo for the management of
the vitiligo in a larger, blinded randomized controlled
trial and as such this study was not designed to allow us
to draw any conclusions about its efficacy. The sample
size was small, thus our findings are preliminary and
definite conclusions about the efficacy and safety of
ginkgo cannot be made. Because the study was open
labeled, not controlled, and not randomized, it is quite
likely that some of the demonstrated benefit may be due
to a placebo effect. However, this is unlikely that all of
the results we report can be accounted for by sponta-
neous repigmentation of vitiligo because these are gen-
erally considered clinically insignificant and cosmetically
undetectable [34,43].
Our primary outcome measure, the VASI, has a degree
of subjectivity associated with it. We attempted to
strengthen the objectivity of the outcomes by using a
trained assessor, and by verifying assessments using digital
photographs. However, both the VASI and VETFI require
the assessor to approximate both the area of vitiligo lesions
and their intensity. Since the assessor was not blinded to
treatment in this open-label pilot study, it is possible that
bias was introduced in the outcome assessment.
The young age of the participants may also have
impacted the results, as younger vitiligo sufferers can
respond more quickly to treatment. It is possible that
the relatively smaller lesion sizes and durations in our
participants could have resulted in over-estimating the
effectiveness of treatment [44]. The Ginkgo biloba
extract itself could have been a source of variability
inherent in studying herbs, but care was taken to ensure
that the herb brand chosen was standardized to ginkgo-
flavonglycosides and terpenoids, both being good mea-
sures of Ginkgo biloba quality. Despite these limitations,
we have estimates of effectiveness that can be used to
estimate a sample size for a larger study. And the results
are compelling enough to proceed with a larger trial.
Conclusions
This pilot study focused on determining the feasibility of
a future large randomized controlled trial of ginkgo for
the treatment of vitiligo. Due to the difficulties of
recruitment of 12 to 18 year old participants, the study
as originally conceived would not have been feasible.
However, with the expansion of participants from 12 to
35 years old, our findings indicate that a larger study is
feasible and ginkgo is worth investigating further as a
potential treatment of vitiligo. Given the limited useful-
ness of current treatments and the frequency of treat-
ment visits required for phototherapy, an over the
counter herb supplement is a welcome possibility for
vitiligo sufferers. Given that our small study found sta-
tistically significant improvement on some secondary
outcome measures, a larger methodologically rigorous
double-blind placebo-controlled randomized clinical
trial is recommended.
Abbreviations
VASI: Vitiligo Area Scoring Index; VETF: Vitiligo European Task Force; GTA:
Greater Toronto Area; PUVA: psoralen with ultra violet light A; UVB: ultra
violet light; NHP: natural health product; IN-CAM: Canadian Interdisciplinary
Network for Complementary & Alternative Medicine Research; CBC: complete
blood count; PTT: partial thromboplastin time; INR: prothrombin time.
Acknowledgements
We wish to thank the Canadian Interdisciplinary Network for Complementary &
Alternative Medicine Research (IN-CAM) for funding the study.
We wish to thank Dr. Antonella Morra for being the study’s supervising
physician.
We also wish to thank Seroyal International Inc. for providing the Ginkgo biloba
supplement free of charge to the study participants. Seroyal did not provide
any other support and had no input over the design or implementation of the
trial, nor did they review this manuscript prior to publication.
Author details
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, 130 Dundas
St East, Suite 305, Mississauga, ON L5A 3V8, Canada.
2Department of
Medicine, Faculty of Medicine, University of Toronto, Toronto, Canada.
3Leslie
Dan Faculty of Pharmacy, University of Toronto, and Department of
Pharmacy and Child Health Evaluative Sciences, The Hospital for Sick
Children, Toronto, Canada.
4Leslie Dan Faculty of Pharmacy, University of
Toronto, Toronto, Canada.
Authors’ contributions
OS conceived of the study, carried out the data collection and review, and
drafted the manuscript. HB conceived of the study, guided the design,
helped to resolve methodological concerns, and critically revised the
manuscript. AT & NS guided the design, helped to resolve methodological
concerns, and critically revised the manuscript. All authors read and
approved the final manuscript.
Competing interests
The study was funded by the Interdisciplinary Network for Complementary &
Alternative Medicine Research (IN-CAM). The study product was provided free
of charge by Seroyal International Inc. who had no input in the design and
conduct of the study nor the interpretation and publishing of the results.
The authors declare no competing interests.
Received: 1 September 2010 Accepted: 15 March 2011
Published: 15 March 2011
References
1. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U: Interventions for vitiligo
[Systematic Review]. Cochrane Database of Systematic Reviews 2007, 3.
2. Sehgal VN, Srivastava G: Vitiligo: compendium of clinico-epidemilogical
features. Indian Journal of Dermatology, Venerology and Leprology 2007,
73(3):149-156.
3. Parsad D, Pandhi R, Juneja A: Effectiveness of oral Ginkgo biloba in
treating limited, slowly spreading vitiligo. Clinical & Experimental
Dermatology 2003, 28(3):285-287.
4. Halder RMMDa, Nootheti PKMDb: Ethnic skin disorders overview.
[Miscellaneous]. Journal of the American Academy of Dermatology 2003,
48((6 Part 2) Supplement):S143-S148.
Szczurko et al. BMC Complementary and Alternative Medicine 2011, 11:21
http://www.biomedcentral.com/1472-6882/11/21
Page 8 of 95. Behl PN, Bhatia RK: 400 cases of vitiligo - A clinicotherapeutic analysis.
Indian Journal of Dermatology 1971, 17:51-53.
6. Mehta HR, Shah KC, Theodore C: Epidemiological study of vitiligo in Surat
area, South Gujarat. Indian Journal of Medical Research 1973, 61:145-154.
7. Barona M, Arrunategui A, Falabella R, Alzate A: An epidemiologic case-
control study in a population with vitiligo. Journal of the American
Academy of Dermatology 1995, 33(4):621-625.
8. Ongenae K, Beelaert L, Van Geel N, Naeyaert JM: Psychosocial effects of
vitiligo. Journal of the European Academy of Dermatology & Venereology
2005, 20:1-8.
9. Porter J, Beuf AH, Nordlund JJ, Lerner AB: The effect of vitiligo on sexual
relationships. Journal of the American Academy of Dermatology 1990,
22(1 Pt. 1):221-222.
10. Porter J, Beuf AH, Nordlund JJ, AB L: Response to cosmetic disfigurement:
Patients with vitiligo. Cutis 1987, 39(6):493-494.
11. Grimes PEMD: New Insights and New Therapies in Vitiligo. [Miscellaneous
Article]. JAMA 2005, 293(6):730-735.
12. Forschner T, Buchholtz S, Stockfleth E: Current state of vitiligo therapy–
evidence-based analysis of the literature. [Review] [30 refs]. Journal der
Deutschen Dermatologischen Gesellschaft 2007, 5(6):467-475.
13. Chu CY, Liu YL, Chiu HC, Jee SH: Dopamine-induced apoptosis in human
melanocytes involves generation of reactive oxygen species. British
Journal of Dermatology 2006, 154(6):1071-1079.
14. Park ES, Kim SY, Na JI, Ryu HS, Youn SW, Kim DS, Yun HY, Park KC:
Glutathione prevented dopamine-induced apoptosis of melanocytes and
its signaling. Journal of Dermatological Science 2007, 47(2):141-149.
15. Namazi M, Chee Leok G: Vitiligo and diet: a theoretical molecular
approach with practical implications. Indian Journal of Dermatology,
Venerology and Leprology 2009, 75(2):116-118.
16. Szczurko O, Boon H: A systematic review of natural health product
treatment for vitiligo. BMC Dermatology 2008, 8(2).
17. Panin Ga, Strumia Rb, Ursini Fc: Topical [alpha]-Tocopherol Acetate in the
Bulk Phase: Eight Years of Experience in Skin Treatment. [Article]. Annals
of the New York Academy of Sciences 2004, 1031:443-447.
18. Ichiro K, Aki MA, Kumiko E, Sang JB: Vitamin D3 and solar irradiation in
the treatment of vitiligo vulgaris. [Miscellaneous]. Journal of the European
Academy of Dermatology & Venereology Supplement 2002, 16(Supplement
1):341.
19. Shigetoshi S: Treatment of vitiligo with Vitamin D3 (tacalcitol).
[Miscellaneous]. Journal of the European Academy of Dermatology &
Venereology Supplement 2002, 16(Supplement 1):275.
20. Siddiqui AH, Stolk LML, Bhaggoe R, Hu R, Schutgens RBH, Westerhof W: L-
Phenylalanine and UVA irradiation in the treatment of vitiligo.
Dermatology 1994, 188(3):215-218.
21. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB: Phenylalanine and
UVA light for the treatment of vitiligo. Archives of Dermatological Research
1985, 277(2):126-130.
22. Rong Y, Geng Z, Lau B: Ginkgo biloba attenuates oxidative stress in
macrophages and endothelial cells. Free Radic Biol Med 1996, , 20:
121-127.
23. Scholtyssek H, Damerau W, Wessel R, Schimke J: Antioxidative activity of
ginkgolides agains superoxide in a aprotic environment. Chem Biol
Interact 1997, 106:183-190.
24. Kim S: Effect of bioflavones of Ginkgo biloba against UVB-induced
cytotoxicity in-vitro. J Dermatol 2001, 28:193-199.
25. Woelk H, Arnoldt K, Kieser M, Hoerr R: Ginkgo biloba special extract EGb
761 in generalized anxiety disorder and adjustmet disorder with anxious
mood: A randomized, double-blind, placebo-controlled trial. Journal of
Psychiatric Research 2007, 41:472-480.
26. Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K: Effect of
chronic administration of Ginko biloba extract or ginkgolide on the
hypothalamic-pituitary-adrenal axis in the rat. Life Sciences 1998,
62:2329-2340.
27. Hoerr R: Behavioural and psychological symptoms of dementia (BPSD):
effects of EGb761. Pharmacopsychiatry 2003, 36(Suppl 1):S56-61.
28. Jezova D, Duncko R, Lassanova M, Kriska M, Moncek F: Reduction of rise in
blood pressure and cortisol release during stress by Ginkgo biloba
extract (EGb 761) in healthy volunteers. Journal of Physiology and
Pharmacology 2002, 53:337-348.
29. Anonymous: Ginko biloba: Monograph. Alternative Medicine Review 1998,
3(1):54-57.
30. World Health Organization: Note for guidance on clinical safety data
management: definitions and standards for expidited reporting. 1995,
CPMP/ICH.377/395.
31. Taieb A, Picardo M: The definition and assessment of vitiligo: a
consensus report of the Vitiligo European Task Force. Pigment Cell
Research 2007, 20:27-35.
32. Hamzavi I, Jain H, McLean D, Shapiro J, Haishan Z, Lui H: Parametric
Modeling of Narrowband UVB Phototherapy for Vitiligo Using a Novel
Quantitative Tool. Archives of Dermatology 2004, 140:677-683.
33. Schulpis CH, Antoniou C, Michas T, Strarigos J: Phenylalanine plus
Utraviolet Light: Preliminary Report of a Promising Treatment for
Childhood Vitiligo. Pediatric Dermatology 6(4):332-335.
34. Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S,
Costin G, Das P: Autoimmune diseases and vitamin D receptor Apa-I
polymorphism are associated with vitiligo in a small inbred Romanian
community. Acta Dermato-Venereologica 2006, 86(3):209-214.
35. Nicolaidu E, Antoniou C, Stratigos A, Katsambas AD: Narrowband
ultraviolet B phototherapy and 308-nm excimer laser in the treatment
of vitiligo: a review. Journal of the American Academy of Dermatology 2009,
60(3):470-477.
36. Chan P, Xia Q, Fu P: Ginkgo biloba leaf extract: biological, medicinal, and
toxicological effects. Journal of Environmental Science and Helath Part C
2007, 25:211-244.
37. Ernst E: The risk-benefit profile of commonly used herbal therapies:
Ginkgo, St. John’s wort, Ginseng, Echinacea, Saw Palmetto, and Kava.
Annals of Internal Medicine 2002, 136:42-53.
38. Natural Standard: Ginkgo (Ginkgo biloba) Monograph. 2008 [http://www.
naturalstandard.com].
39. Dugoua J-J, Mills E, Perri D, Koren G: Safety and efficacy of Ginkgo
(Ginkgo biloba) during pregnancy and lactation. Canadian Journal of
Clinical Pharmacology 2006, 13(3):e277-e284.
40. Health Canada: Adverse Drug Reaction Database. 2008.
41. Sparreboom A, Cox CM, Acharya RM, Figg DW: Herbal Remedies in the
United States: Potential Adverse Interactions with Anticancer Agents.
Journal of Clinical Oncology 2004, 22(12):2489-2503.
42. Koek MB SV, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA,
Buskens E: Cost effectiveness of home ultraviolet B phototherapy for
psoriasis: economic evaluation of a randomised controlled trial (PLUTO
study). BMJ 2010, 340(April 20):1490.
43. Koranne R, Sachdeva K: Vitiligo. International Journal of Dermatology 1988,
27(10):676-681.
44. Scherschun L, Kim J, Lim HW: Narrow-band ultraviolet B is a useful and
well-tolerated treatment for vitiligo. J Am Acad Dermatol 2001,
44(6):999-1003.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1472-6882/11/21/prepub
doi:10.1186/1472-6882-11-21
Cite this article as: Szczurko et al.: Ginkgo biloba for the treatment of
vitilgo vulgaris: an open label pilot clinical trial. BMC Complementary and
Alternative Medicine 2011 11:21.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Szczurko et al. BMC Complementary and Alternative Medicine 2011, 11:21
http://www.biomedcentral.com/1472-6882/11/21
Page 9 of 9